Geron is executing in the clinic with success in IMerge, and other studies are set to read out in late 2023, 2024, and beyond. Find out why GERN stock is a Buy.

Research and Development Expenses: $15.1 million for Q1 2025, down from $29.4 million in Q1 2024. Selling, General, and Administrative Expenses: $40 million for Q1 2025, up from $27.1 million in ...

Geron Corporation (NASDAQ:GERN) has had a rather quiet 2017 so far.The last bit of good news we heard was the announcement that Johnson and Johnson's (NYSE:JNJ) Janssen division had concluded that ...

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company. The one-month return of Geron Corporation (NASDAQ:GERN) was -11.88%, and its shares lost 58.89% of their value over ...

We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Geron Corporation (NASDAQ:GERN) stands against the other ...

Geron Corporation (NASDAQ:GERN) is one of the 13 Stocks Under $5 With High Upside Potential. Log In Sign Up Premium #1 AI Stock to Buy. ... Let’s face it, complacency breeds stagnation.

Below is Validea's guru fundamental report for GERON CORP (GERN). Of the 22 guru strategies we follow, GERN rates highest using our P/B Growth Investor model based on the published strategy of ...

Geron (GERN), the biopharmaceutical company behind the approved telomerase inhibitor for specific lower-risk myelodysplastic syndromes, has experienced significant success with its product RYTELO.

GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm. March 14, 2025 07:36 PM Eastern Daylight Time. LOS ANGELES--(BUSINESS WIRE) ...